Drug intelligence / Profile preview

MP010

Development stage: Preclinical
Lead developer: MedPacto
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

MP010 is a bifunctional fusion protein being developed by MedPacto, Inc. as a bispecific agent targeting the tumor microenvironment (TME). It is designed to simultaneously bind to Extra Domain B fibronectin (EDB-FN), a component of the extracellular matrix overexpressed in tumors, and inhibit Transforming Growth Factor-beta (TGF-β). By selectively localizing to the TME via EDB-FN binding, MP010 traps TGF-β to neutralize its immunosuppressive effects, thereby promoting immune cell infiltration and inducing cancer cell death. The drug is currently in preclinical development for solid tumors, with an Investigational New Drug (IND) application planned for 2026.

Targets

ED-B (Fibronectin extra domain B)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on MP010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MP010.

Explore the full profile